Copaxone

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Multiple SclerosisMacular Degeneration

138 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

1

Copaxone

Teva

Approved

162

Rinvoq

AbbVie

Phase 3

13

Cytoxan

BBaxter Healthcare Corporation

Phase 3

94

Versed

CConrado Roberto Hoffmann Filho

Phase 3

25

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

26

Vumerity

Biogen

Phase 3

57

Mayzent

Novartis

Phase 3

28

Antihistamine

Arrowhead Pharmaceuticals

Phase 3

29

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

310

Frexalimab

Sanofi

Phase 3

2Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Multiple Sclerosis16 trials

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Withdrawn·Biogen·Phase 2·NCT04079088

Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate

Unknown status·SSheba Medical Center·N/A·NCT00331747·20 enrolled

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Terminated·Biogen·Phase 3·NCT01058005·84 enrolled

Show 13 more trials

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

Completed·UUniversity of California, San Francisco··NCT00819195·17 enrolled

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Completed·Teva··NCT03209479·1,332 enrolled

Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran

Completed·CCinnagen··NCT04928313·368 enrolled

Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate

Terminated·Teva·Phase 4·NCT00203047·414 enrolled

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Terminated·NNeurognostics··NCT00398528·48 enrolled

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome

Completed·Teva·Phase 3·NCT00666224·481 enrolled

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Completed·Sanofi·Phase 2·NCT00475865·123 enrolled

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Completed·Sanofi·Phase 2·NCT00811395·182 enrolled

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Completed·Teva·Phase 2·NCT00203073·40 enrolled

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

Unknown status·—·Phase 4·NCT00910598·60 enrolled

Treatment of Multiple Sclerosis With Copaxone and Albuterol

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00039988·40 enrolled

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Active, not recruiting·Biogen··NCT05688436·1,178 enrolled

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Terminated·Sanofi·Phase 3·NCT03368664·16 enrolled

Relapsing-Remitting Multiple Sclerosis6 trials

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

Completed·FFred Lublin·Phase 3·NCT00211887·1,008 enrolled

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

Completed·Biogen·Phase 3·NCT00451451·1,417 enrolled

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

Completed·Teva·Phase 3·NCT01067521·1,404 enrolled

Show 3 more trials

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Completed·Teva·Phase 3·NCT00337779·1,155 enrolled

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Completed·Teva·Phase 3·NCT01167426·148 enrolled

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Terminated·Teva·Phase 3·NCT01578785·178 enrolled

Safety and Efficacy3 trials

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline

Completed·Teva·Phase 2·NCT00203112·44 enrolled

Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine

Completed·Teva·Phase 2·NCT00203099·18 enrolled

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Terminated·Novartis·Phase 3·NCT01633112·1,064 enrolled

Rett syndrome2 trials

Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Completed·MMontefiore Medical Center·Phase 2·NCT02153723·10 enrolled

An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome

Unknown status·SSheba Medical Center·Phase 1·NCT02023424·10 enrolled

Effectiveness2 trials

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Completed·Teva·Phase 2·NCT00202982·90 enrolled

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Completed·Teva·Phase 4·NCT00203021·208 enrolled

13 more indications

Induction Therapy1 trial

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

Completed·UUniversity of Colorado, Denver·Phase 2·NCT01569451·53 enrolled

Treatment1 trial

Treatment Interruption of Natalizumab

Completed·Biogen·Phase 2·NCT01071083·175 enrolled

Disease Progression1 trial

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Terminated·Teva·Phase 4·NCT00202995·91 enrolled

Crohn's Disease1 trial

A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2·NCT00731172·50 enrolled

Amyotrophic Lateral Sclerosis1 trial

Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)

Completed·Teva·Phase 2·NCT00326625·366 enrolled

Coagulation1 trial

Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation

Unknown status·FFederal University of São Paulo·Phase 4·NCT00677664·30 enrolled

Outcome1 trial

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Completed·Novartis·Phase 4·NCT01534182·298 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of GTR in Comparison to Copaxone®

Completed·SSynthon BV·Phase 3·NCT01489254·794 enrolled

Secondary Progressive Multiple Sclerosis1 trial

Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients

Completed·IIsfahan University of Medical Sciences·Phase 2/3·NCT03315923·84 enrolled

MPR1 trial

A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®

Completed·Teva·Phase 4·NCT00239993·50 enrolled

Fatigue1 trial

FOCUS Fatigue Outcome in Copaxone USers

Completed·Sanofi·Phase 4·NCT00267319·111 enrolled

Optic Neuritis1 trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Completed·Teva·Phase 3·NCT00856635·44 enrolled

Unspecified1 trial

Safety of New Formulation of Glatiramer Acetate

Completed·Teva·Phase 3·NCT00947752·147 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News